• Trial also achieves statistical significance in key secondary endpoints
  • Novavax to submit a U.S. BLA under FDA’s accelerated approval pathway
  • Company to host investor conference call today at 8:30 a.m. EDT

Read more…

The post Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial appeared first on Healthier Environment Living Program.